淋巴瘤中可溶性编程细胞死亡配体-1 (sPD-L1) 的预后值:系统性审查和元分析

Yangyang Ding1, Cheng Sun2, Linhui Hu1

  • 1Department of Hematology/Hematological Lab, The Second Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.

Annals of hematology
|June 29, 2023
PubMed
概括

高可溶性编程细胞死亡配体1 (sPD-L1) 水平表明淋巴瘤患者的预后较差,包括那些患有扩散性大B细胞淋巴瘤 (DLBCL) 和NK/T细胞淋巴瘤 (NK/TCL) 患者. 这一发现表明sPD-L1是一种潜在的预后生物标志物.

相关概念视频